Cover Image
市場調查報告書

肛門癌:開發平台分析

Anal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213060
出版日期 內容資訊 英文 115 Pages
訂單完成後即時交付
價格
Back to Top
肛門癌:開發平台分析 Anal Cancer - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 115 Pages
簡介

肛門癌發生於肛門,常見的症狀有直腸出血,直腸發癢,肛門開口部腫瘤和疙瘩,肛門周圍會感到疼痛和腫。原因有人類乳突病毒的感染和抽煙,免疫力低落等。

本報告提供肛門癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃相關資訊等,同時加上最新的新聞和發表等資料。

簡介

  • 調查範圍

肛門癌 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥開發作的企業

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8370IDB

Summary

Global Markets Direct's, 'Anal Cancer - Pipeline Review, H2 2016', provides an overview of the Anal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anal Cancer
  • The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anal Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Anal Cancer - Overview
    • Pipeline Products for Anal Cancer - Comparative Analysis
  • Anal Cancer - Therapeutics under Development by Companies
  • Anal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Anal Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Anal Cancer - Products under Development by Companies
  • Anal Cancer - Products under Investigation by Universities/Institutes
  • Anal Cancer - Companies Involved in Therapeutics Development
    • Advaxis, Inc.
    • Amgen Inc.
    • Cell Medica Limited
    • Eli Lilly and Company
    • Genticel S.A.
    • ISA Pharmaceuticals B.V.
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Oryx GmbH & Co. KG
    • PDS Biotechnology Corporation
    • Sun Pharma Advanced Research Company Ltd.
    • Taiwan Liposome Company, Ltd.
  • Anal Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • axalimogene filolisbac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for HPV Associated Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMD-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GTL-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel albumin free - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panitumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDR-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDS-0101A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prexasertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vicoryx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anal Cancer - Dormant Projects
  • Anal Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 08, 2016: Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
      • Jun 05, 2016: Nivolumab shows promise in first-ever trial for patients with refractory, metastatic anal cancer
      • Dec 16, 2015: FDA Lifts Advaxis Clinical Hold On Axalimogene Filolisbac
      • Dec 14, 2015: Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer
      • Dec 07, 2015: ISA Pharmaceuticals' ISA101 Studied in Phase II Combination Trial with Checkpoint Inhibitor Nivolumab
      • Nov 02, 2015: Advaxis Provides Additional Information on Clinical Hold
      • Apr 06, 2015: Advaxis and RTOG Foundation to Collaborate on Pivotal Phase 2/3 Clinical Trial of ADXS-HPV in Anal Cancer
      • Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer
      • Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience
      • Sep 16, 2013: ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia
      • Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV
      • Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV
      • Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy
      • Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anal Cancer, H2 2016
  • Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Anal Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Anal Cancer - Pipeline by Amgen Inc., H2 2016
  • Anal Cancer - Pipeline by Cell Medica Limited, H2 2016
  • Anal Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Anal Cancer - Pipeline by Genticel S.A., H2 2016
  • Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2016
  • Anal Cancer - Pipeline by Novartis AG, H2 2016
  • Anal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Anal Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
  • Anal Cancer - Pipeline by PDS Biotechnology Corporation, H2 2016
  • Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Anal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Anal Cancer - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Anal Cancer, H2 2016
  • Number of Products under Development for Anal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top